Significance of cyclooxygenase-2 in prognosis, targeted therapy and chemoprevention of NSCLC. (April 2007)

• Record Type: Journal Article
• Authors: Lee, Jay M; Mao, Jenny T; Krysan, Kostyantyn; Dubinett, Steven M
• Is Part Of: Future oncology. Volume 3:Number 2(2007)
• Page Start: 149
• Page End: 153
• Publication Date: 2007-04
• Subjects: Cox-2 -- cyclo-oxygenase-2 -- gene mutation -- inflammation -- Ki-67 -- lung cancer -- non-small-cell lung cancer -- oncogene -- p53 -- proliferation index; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/14796694.3.2.149
• Languages: English
• ISSNs: 1479-6694

Abstract

Evaluation of: Tsubochi H, Nobuyuki S, Hiyama M et al. : Combined analysis of cyclooxygenase-2 expression with p53 and Ki-67 in nonsmall cell lung cancer. Ann. Thorac. Surg. 82(4), 1198––1204 (2006). The report by Tsubochi and colleagues adds to the growing evidence indicating that tumor cyclo-oxygenase (Cox)-2 has a multifaceted role in conferring the malignant phenotype of non-small-cell lung cancer (NSCLC), and provides insight into the use of markers to provide prognostic information. Cox-2 has been implicated in apoptosis resistance, angiogenesis, decreased host immunity and enhanced invasion and metastasis, and, thus, has a critical involvement in carcinogenesis. This study, as well as others, has contributed to providing an insight into opportunities for targeted therapies in NSCLC. Cox-2 is one of the novel targets being studied for lung cancer therapy and chemoprevention.